BVXP:LSE-Bioventix PLC (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 4,175.00

Change

0.00 (0.00)%

Market Cap

GBX 0.22B

Volume

6.21K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. The company was founded in 2003 and is based in London, the United Kingdom. Address: 27-28 Eastcastle Street, London, United Kingdom, W1W 8DH

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
GNS:LSE Genus plc

-70.00 (-1.36%)

GBX3.32B 69.02 33.83
HCM:LSE HUTCHMED (China) Limited

+32.50 (+8.42%)

GBX3.12B 17.41 N/A
ABC:LSE Abcam plc

-8.00 (-0.58%)

GBX3.08B 247.50 93.40
OXB:LSE Oxford Biomedica plc

N/A

GBX1.07B N/A 250.84
PRTC:LSE PureTech Health plc

+6.50 (+1.84%)

GBX1.03B 256.79 28.28
ERGO:LSE Ergomed plc

+5.00 (+0.39%)

GBX0.63B 67.19 34.71
SLN:LSE Silence Therapeutics plc

-15.00 (-2.34%)

GBX0.57B N/A N/A
AVCT:LSE Avacta Group Plc

-11.20 (-4.98%)

GBX0.54B N/A N/A
SNG:LSE Synairgen plc

-5.80 (-3.48%)

GBX0.33B N/A N/A
ARIX:LSE Arix Bioscience plc

-9.00 (-4.86%)

GBX0.23B 1.98 N/A

ETFs Containing BVXP

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.79% 38% F 16% F
Dividend Return 0.98% 100% A+ 64% D
Total Return -3.81% 43% F 19% F
Trailing 12 Months  
Capital Gain -0.36% 29% F 18% F
Dividend Return 2.27% 100% A+ 58% F
Total Return 1.91% 32% F 20% F
Trailing 5 Years  
Capital Gain 331.52% 88% B+ 95% A
Dividend Return 31.63% 100% A+ 89% B+
Total Return 363.15% 88% B+ 94% A
Average Annual (5 Year Horizon)  
Capital Gain 35.82% 63% D 86% B
Dividend Return 2.43% 50% F 83% B
Total Return 38.25% 63% D 85% B
Risk Return Profile  
Volatility (Standard Deviation) 34.02% 80% B- 36% F
Risk Adjusted Return 112.45% 98% A+ 95% A
Market Capitalization 0.22B 74% C 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 31.82 58% F 29% F
Price/Book Ratio 21.23 16% F 4% F
Price / Cash Flow Ratio 28.31 16% F 18% F
EV/EBITDA 27.51 70% C- 25% F
Management Effectiveness  
Return on Equity 68.73% 100% A+ 99% A+
Return on Invested Capital 59.61% 100% A+ 98% A+
Return on Assets 45.01% 100% A+ 100% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.26 71% C- 90% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector